Tara Fischer
Psychiatric/Mental Health · Coral Gables, FLNPI 1225669880
Payments from drug & device makers
Across 590 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$980
- Neurocrine Biosciences, Inc.$911
- plus $3K from 19 others
What the payments were for
- Food & beverage$10,699100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 85 | $1,503 |
| AbbVie | 82 | $1,447 |
| Alkermes, Inc. | 65 | $1,290 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $1,193 |
| Lundbeck LLC | 63 | $980 |
| Neurocrine Biosciences, Inc. | 26 | $911 |
| Teva Pharmaceuticals USA, Inc. | 38 | $631 |
| Vanda Pharmaceuticals Inc. | 32 | $628 |
| Almatica Pharma LLC | 35 | $583 |
| Sunovion Pharmaceuticals Inc. | 52 | $459 |
| Axsome Therapeutics, Inc. | 13 | $307 |
| Supernus Pharmaceuticals, Inc. | 8 | $143 |
| Idorsia Pharmaceuticals US Inc | 7 | $132 |
| E.r. Squibb & Sons, L.L.C. | 5 | $116 |
| Bausch Health US, LLC | 3 | $57 |
| Indivior Inc. | 2 | $56 |
| Corium, LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $42 |
| Orexo US, Inc. | 2 | $34 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $19 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,711 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $207,213 |
| Invega SustennaPaliperidone Palmitate | 55 | $176,336 |
| LybalviOlanzapine/Samidorphan Malate | 33 | $52,813 |
| RexultiBrexpiprazole | 27 | $43,081 |
| Abilify MaintenaAripiprazole | 13 | $34,482 |
| VraylarCariprazine Hcl | 13 | $17,569 |
| Lurasidone Hcl | 47 | $15,093 |
| Chlorpromazine Hcl | 57 | $11,989 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $11,230 |
| Risperidone | 285 | $8,013 |
| Trazodone Hcl | 539 | $6,966 |
| Quetiapine Fumarate | 339 | $6,510 |
| Aripiprazole | 133 | $3,596 |
| Ziprasidone Hcl | 29 | $3,491 |
| Divalproex Sodium | 129 | $2,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $911 | $207,21324 claims |
| Johnson & JohnsonInvega Sustenna | $42 | $176,33655 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,503 | $77,56340 claims |
| Alkermes, Inc.Lybalvi | $1,290 | $52,81333 claims |
| AbbVieVraylar | $1,447 | $17,56913 claims |
| Orexo US, Inc.Zubsolv | $34 | $11,23013 claims |
| Almatica Pharma LLCSertraline Hcl | $583 | $684179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Coral Gables
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.